DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alcoholic Hepatitis , historical and forecasted epidemiology as well as the Alcoholic Hepatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

DelveInsight has launched a new report on Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast-2030

Acute Myeloid Leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized by a clonal proliferation and impaired differentiation of myeloid precursors with diverse outcomes. It is the fastest growing cancer that occurs when the bone marrow begins to form cells that have not yet completely matured as blasts. These cells crowd the bone marrow, preventing it from making normal blood cells and the abnormal (leukemia) cells begin to crowd out the normal white blood cells, red blood cells, and platelets that the body needs. In AML, the bone marrow also makes abnormal red cells and platelets, and thus the blood cells do not develop, and it gets difficult to ward off infections..

AML is one of the most common types of leukemia in adults, and even being rare, it is the leading cause of leukemia-related deaths. It is found to be slightly more common among men as compared to women.

 

Request for sample page: – Acute Myeloid Leukemia Sample Page Link

 

Acute Myeloid Leukemia Epidemiology  

The Acute Myeloid Leukemia epidemiology division provides insights about historical and current Acute Myeloid Leukemia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Some of the Report Key facts:-

1. AML accounts for <3% of all cancers, and 25% of all leukemia in adults. Worldwide, the incidence of AML was reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years.
2. The incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people age   
3. According to a cross-national study using US and England data, it has been found that the overall risk of mortality for AML was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis.

 

Report Key Benefits

1. Acute Myeloid Leukemia  market report covers a descriptive overview and comprehensive insight of the Acute Myeloid Leukemia epidemiology Acute Myeloid Leukemia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Acute Myeloid Leukemia market report provides insights on the current and emerging therapies.

3. Acute Myeloid Leukemia market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Acute Myeloid Leukemia market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia market.

 

“According to the cross-national study by Xie et al., the survival patterns in individuals diagnosed with AML reported the mortality risk, which varied substantially across AML subtypes between England and US. This difference was significant in AML inv (16), which showed a higher risk of mortality than their US counterparts. In other subtypes, the observed mortality rate reported in AML was with minimal differentiation, AML without maturation, and AML with maturation was [0.54, 0.25–1.17; 0.38, 0.20–0.74, and 0.52, 0.31–0.86, respectively] not differed significantly.”

 

Some of the key companies working on AML that are given below-

1. Novartis Pharmaceutical Company
2. Pfizer Pharmaceutical Corporation
3. Astellas Pharmaceutical Company

 

Name of covered Drugs are given below.

1. RYDAPT
2. MYLOTARG
3. XOSPATA

 

Table of Contents

1. Key Insights

2. Executive Summary of Acute Myeloid Leukemia

3. Competitive Intelligence Analysis for Acute Myeloid Leukemia

4. Acute Myeloid Leukemia: Market Overview at a Glance

5. Acute Myeloid Leukemia: Disease Background and Overview

6. Patient Journey

7. Acute Myeloid Leukemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Acute Myeloid Leukemia Treatment

11. Marketed Products

13. Acute Myeloid Leukemia: Seven Major Market Analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Myeloid Leukemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this Acute Myeloid Leukemia Report?

• The report will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia market
• To understand the future market competition in the Acute Myeloid Leukemia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia market
• To understand the future market competition in the Acute Myeloid Leukemia market

 

Related Reports

                     1.  Acute Myeloid Leukemia  Pipeline Insights 2020      

Acute Myeloid Leukemia (AML) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Myeloid Leukemia (AML) market.

                     2. Acute Myeloid Leukemia  Epidemiology Forecast to 2030

DelveInsight’s Acute Myeloid Leukemia (AML) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Acute Myeloid Leukemia (AML) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/